Stivarga (regorafenib) — United Healthcare

Initial criteria

• One of the following: (a) BOTH of the following: Diagnosis of gallbladder cancer, extrahepatic cholangiocarcinoma, or intrahepatic cholangiocarcinoma AND Disease is unresectable, gross residual (R2), or metastatic OR (b) BOTH of the following: Diagnosis of hepatocellular carcinoma AND Used as subsequent-line therapy for disease progression

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Stivarga therapy

Approval duration

12 months